Key Developments: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

1.37USD
22 Sep 2014
Price Change (% chg)

$0.01 (+0.74%)
Prev Close
$1.36
Open
$1.35
Day's High
$1.38
Day's Low
$1.34
Volume
822,187
Avg. Vol
1,076,719
52-wk High
$1.74
52-wk Low
$0.99

Search Stocks

Latest Key Developments (Source: Significant Developments)

AEterna Zentaris Inc Completes $7.8 Million Registered Direct Offering
Tuesday, 30 Jul 2013 06:00pm EDT 

AEterna Zentaris Inc announced that it has completed its previously announced registered direct offering of $7.8 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $7 million. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used to continue to fund the Company's ongoing drug development activities, primarily for the advancement of its zoptarelin doxorubicin program, secondly for its macimorelin acetate program, as well as for general corporate purposes and working capital. Burrill Securities LLC acted as the exclusive placement agent for the transaction. As of July 30, 2013 and after issuing 5.2million common shares at the closing of this offering, the Company had approximately 31.2 million common shares issued and outstanding, without giving effect to or assuming the exercise of any outstanding warrants.  Full Article

AEterna Zentaris Inc Announces Dismissal Of Class Action Lawsuit
Thursday, 6 Jun 2013 04:05pm EDT 

AEterna Zentaris Inc announced that the previously disclosed purported class action lawsuit filed against the Company and certain of its officers (the Defendants) by Faruqi & Faruqi LLP in the United States District Court for the Southern District of New York has been entirely dismissed with prejudice and without leave to amend. No payment was made by any of the Defendants to the plaintiff or his counsel in connection with the lawsuit. The plaintiff has 30 days from the docketing of the final judgment to file a notice of appeal, if he determines to do so.  Full Article

AEterna Zentaris Inc Announces Transfer Of Manufacturing Rights Related To Cetrotide To Merck KGaA
Wednesday, 17 Apr 2013 07:30am EDT 

AEterna Zentaris Inc announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA of Darmstadt, Germany (Merck Serono), in all jurisdictions. Subject to the satisfaction of customary closing conditions, the transaction is expected to be completed on or about October 1, 2013, at which time Aeterna Zentaris would receive a one-time payment of EUR2.5 million, or approximately $3.2 million and certain other payments. In addition, the Company has also entered into a transitional services agreement with Merck KGaA under which the Company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide in consideration for the payment of a monthly fee to the Company throughout such period.  Full Article

AEterna Zentaris Inc Announces Appointment Of New President and Chief Executive Officer
Monday, 15 Apr 2013 08:00am EDT 

AEterna Zentaris Inc announced that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.  Full Article

AEterna Zentaris Inc Announces Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Theraphy Result
Tuesday, 11 Dec 2012 07:30am EST 

AEterna Zentaris Inc announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin Lymphoma ("HL"), suggesting that this subgroup could represent the target population for future studies. Data were presented by Anna Guidetti, MD, of the Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during a poster session at the American Society of Hematology annual meeting in Atlanta, Georgia. Based on tumor response to the initial 4 week perifosine therapy, 36 of 40 patients who achieved less than PR were subsequently administered the perifosine/sorafenib combination therapy. Median duration of combination therapy was 4 months (range: 2-18). Four CLL patients who achieved at least a PR with perifosine alone, went off-study and continued with single-agent therapy with a median duration of response of 10 months (range 4-21). The most common drug-related toxicities were grade 1-2 diarrhea (25%), joint pain (22%), weight loss (19%), anemia (17%), and thrombocytopenia (9%). Hand-foot skin reaction was observed in 25% (grade 2) and 14% (grade 3) of patients. Grade 4 neutropenia was observed in only 1 patient. Two responding patients experiencing grade 3 pneumonitis discontinued treatment.  Full Article

AEterna Zentaris Inc Announces Closing Of $16.5 Million Public Offering Of Common Shares And Warrants
Wednesday, 17 Oct 2012 09:24am EDT 

AEterna Zentaris Inc announced the closing of its previously announced public offering of 6.6 million units (the Offering) generating net proceeds of $15.2 million, with each unit consisting of one common share and 0.45 of a warrant to purchase one common share, at a purchase price of $2.50 per unit. Each warrant is exercisable for a period of five years at an exercise price of $3.45 per share. Roth Capital Partners, LLC, acted as the sole managerfor the Offering. The Company intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, particularly for the continued development of perifosine in multiple myeloma and the advancement of its AEZS-108 and AEZS-130 programs, as well as for general corporate purposes and working capital.  Full Article

AEterna Zentaris Inc Announces Pricing of $16.5 Million Public Offering Of Common Shares And Warrants
Friday, 12 Oct 2012 08:55am EDT 

AEterna Zentaris Inc announced that the pricing of its previously announced public offering of 6.6 million units (the Offering), with each unit consisting of one common share and 0.45 of a warrant to purchase one common share, at a purchase price of $2.50 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of $3.45 per share. Net proceeds from the Offering are expected to be approximately $15.2 million, after deducting underwriting commissions and other expenses related to the Offering. Roth Capital Partners, LLC is acting as the sole manager for the Offering. The Offering is expected to close on or about October 17, 2012, subject to customary closing conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approvals of the Toronto Stock Exchange and the NASDAQ Global Market.  Full Article

AEterna Zentaris Inc Announces Proposed Public Offering of Common Shares and Warrants
Thursday, 11 Oct 2012 04:13pm EDT 

AEterna Zentaris Inc announced that it has commenced an underwritten public offering of units (the Offering), consisting of common shares and warrants to purchase common shares. Roth Capital Partners, LLC, is acting as the sole book-running manager for the Offering. The Offering is subject to market conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.  Full Article

Search Stocks